Powl Brian T.'s Form 4 filing
Fate Therapeutics IncFATE · filed Jul 6, 2023
- Accession no.
- 0001209191-23-041611
- Filed
- Jul 6, 2023
- Trade date
- Jul 5, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $18.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Powl Brian T.CIK 0001934232 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 5, 2023 | Common Stock | SSaleDisposed | −3,854 | $4.87F2 | −$18,768.98 | 41,146 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold from $4.82 to $4.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth this footnote.
Referenced by the price of 1 transaction in Table I.